Apr. 6
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2024 (the “Grant Date”), ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)